Our Pricing

Orlistat vs Mounjaro: Evidence-Based Comparison for UK Patients

Published on: June 03, 2026

When comparing orlistat vs mounjaro weight loss UK treatments, you're looking at two fundamentally different approaches: orlistat blocks dietary fat absorption through your digestive system, whilst Mounjaro (tirzepatide) regulates appetite hormones through weekly injections. At Cured Pharmacy, our UK prescribers assess which treatment aligns with your medical history, lifestyle preferences, and weight loss goals—all through a free online consultation that takes under three minutes.

How Orlistat and Mounjaro Work Differently

Orlistat functions as a lipase inhibitor, blocking approximately 25% of dietary fat from being absorbed in your intestinal tract [1]. When you take orlistat capsules with meals containing fat, the unabsorbed fat passes through your digestive system and is eliminated in stools. This mechanism requires consistent adherence to a reduced-calorie, lower-fat diet to minimise gastrointestinal side effects and maximise weight loss outcomes.

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for chronic weight management [2]. Unlike orlistat's digestive approach, tirzepatide activates two incretin hormone pathways that regulate blood glucose levels, slow gastric emptying, and reduce appetite signals in the brain. Clinical trials demonstrate this dual mechanism produces substantially greater weight reduction compared to single-pathway treatments.

Clinical Effectiveness: What the Evidence Shows

In the XENDOS trial, patients taking orlistat 120mg three times daily alongside lifestyle modifications achieved an average 10.2% total body weight loss over four years, compared to 6.1% with placebo [1]. Orlistat demonstrates consistent but modest weight reduction when combined with dietary fat restriction below 30% of total calories.

The SURMOUNT-1 trial showed patients receiving the highest Mounjaro dose (15mg weekly) achieved an average 22.5% body weight reduction over 72 weeks—more than double the outcomes observed with orlistat [2]. In SURMOUNT-3, participants who continued tirzepatide after initial weight loss maintained an additional 5.5% weight reduction, whilst those switching to placebo regained 14% [3].

For UK patients, these differences translate to distinct clinical scenarios. Orlistat may suit individuals preferring oral medication who can commit to strict dietary fat control, whilst Mounjaro typically produces greater weight loss for those comfortable with weekly self-injection and meeting NICE eligibility criteria.

Real-World Weight Loss Expectations

Your UK prescriber will set realistic expectations based on your starting BMI, metabolic health, and treatment choice. Orlistat users typically lose 5-10% of body weight over six months when adhering to a reduced-fat diet [1]. Mounjaro patients often achieve 15-22% weight reduction over 12-18 months, though individual responses vary considerably [2][3]. Both treatments require ongoing lifestyle modifications—medication alone does not produce sustained weight management.

Side Effects and Tolerability Profiles

Orlistat's side effects relate directly to its fat-blocking mechanism. Approximately 15-30% of users experience oily stools, faecal urgency, or increased bowel movements—particularly when consuming meals exceeding recommended fat content [1]. These gastrointestinal effects typically diminish as patients adapt their dietary fat intake, though some individuals discontinue treatment due to tolerability concerns.

Mounjaro's most common side effects involve the gastrointestinal system but differ in character: nausea (29-44% of patients), diarrhoea (19-21%), and vomiting (8-13%) occur most frequently during dose escalation [2]. These effects generally decrease over 4-8 weeks as your body adjusts to each dose level. Rare but serious risks include pancreatitis and thyroid C-cell tumours (observed in rodent studies), requiring careful patient selection and monitoring.

Managing Treatment Side Effects

Our superintendent pharmacist Tarun Kumar advises patients starting orlistat to maintain a food diary tracking fat intake per meal, keeping dietary fat below 15 grams per meal to minimise gastrointestinal symptoms. For Mounjaro users, eating smaller portions, avoiding high-fat meals, and staying well-hydrated during the first month significantly improves tolerability during dose titration.

Dosing, Administration and Treatment Duration

Orlistat is taken as 120mg capsules three times daily with each main meal containing fat, or up to one hour after eating. If you skip a meal or eat a fat-free meal, you omit that dose. Treatment typically continues for six months initially, with reassessment by your prescriber—NICE guidance recommends discontinuing orlistat if you haven't lost at least 5% of initial body weight after 12 weeks [4].

Mounjaro follows a structured dose escalation schedule starting at 2.5mg weekly for four weeks, increasing every four weeks through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum 15mg weekly based on tolerability and weight loss response [2]. You self-administer injections subcutaneously using pre-filled KwikPens, rotating injection sites in your abdomen, thigh, or upper arm. Treatment duration is typically long-term, as weight regain commonly occurs after discontinuation.

Eligibility Criteria and Prescribing Guidelines

UK prescribers can recommend orlistat for adults with BMI ≥30 kg/m², or BMI ≥28 kg/m² with weight-related comorbidities such as type 2 diabetes or hypertension [4]. Orlistat is contraindicated in chronic malabsorption syndrome, cholestasis, pregnancy, and breastfeeding. Your prescriber will assess for medications affected by fat-soluble vitamin absorption, including warfarin and levothyroxine.

Mounjaro prescribing follows NICE guidance for GLP-1 receptor agonists: BMI ≥35 kg/m² (or ≥32.5 kg/m² for certain ethnic groups), or BMI ≥30 kg/m² with at least one weight-related comorbidity [4]. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease. Your UK prescriber reviews your complete medical history during the online consultation to determine suitability.

Starting Your Clinical Assessment

All prescription weight loss treatments at Cured Pharmacy require clinical assessment by a UK-registered prescriber. Our online consultation takes under three minutes and covers your medical history, current medications, weight loss goals, and lifestyle factors. Your prescriber determines which treatment—if any—is clinically appropriate and safe for your individual circumstances.

Cost Comparison and Treatment Value

Orlistat represents the most affordable prescription weight loss option at Cured Pharmacy, starting from £135.00 for generic formulations. Branded Xenical orlistat costs from £135.00, whilst over-the-counter Alli 60mg (half-strength) starts from £135.00. These prices reflect 84-capsule supplies, providing approximately four weeks of treatment when taken three times daily.

Mounjaro pricing reflects its advanced dual-agonist technology and superior clinical outcomes, starting from £124.99 per monthly supply at Cured Pharmacy. Whilst the upfront cost exceeds orlistat, many patients find the greater average weight loss, weekly dosing convenience, and reduced dietary restrictions justify the investment. Your prescriber discusses treatment costs transparently during consultation, with no hidden fees—the price you see includes medication, prescriber review, and discreet delivery.

Scientific References

1. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment and lifestyle modifications.